Displaying 13 - 24 of 34
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
Metabolism, Alcohol & Toxicity
6

Novo Nordisk:Clinical harmonisation for improving NASH diagnosis - NAFLD Summit 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
General Hepatology
5

Orphalan: Chelating Evidence: Achieving More for Patients with Wilson’s Disease - ILC 2022

View
Displaying 13 - 24 of 34